The lupus Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lupus Hub cannot guarantee the accuracy of translated content. The lupus and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lupus Hub is an independent medical education platform, supported through a grant from AstraZeneca. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders..
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lupus content recommended for you
Comparative risk of infection in patients with SLE treated with belimumab versus oral immunosuppressants
Test your knowledge! Take our quick quiz before and after you read this article to find out if you improved your knowledge. Results help us to improve content and continually provide open-access education.
Question 1 of 1
When comparing belimumab with oral immunosuppressants, a retrospective study of 21,481 patient records found that the adjusted cumulative incidence of serious infection in one year with belimumab was:
A
B
C
D
As previously reported on the Lupus Hub, patients with systemic lupus erythematosus (SLE) are at increased risk of serious infection, which is a leading cause of mortality and morbidity for these patients. The risk of infection is primarily attributed to the disease state of SLE, characterized by reduced complement cascade factors and cell surface receptor expression, and poor clearance of immune complexes. Treatment of these patients with immunosuppressants, such as steroid-sparing agents and glucocorticoids, increases the risk of serious infection and hospitalization.
Prior studies have demonstrated an increased risk of infection and hospitalization associated with oral immunosuppressants such as methotrexate, azathioprine, or mycophenolate when compared with hydroxychloroquine. However, the comparative risk of infection with biologic immunosuppressant belimumab versus oral immunosuppressants in patients with SLE is still unknown.
To bridge this knowledge gap, Materne et al.1 recently published an article in Arthritis & Rheumatology comparing the risk of infection with belimumab versus either azathioprine, methotrexate, or mycophenolate in patients with non-renal SLE. Patients were identified from TriNetX, a United States multicenter electronic health record database which includes >90,000 patient records for patients with SLE.
The baseline patient characteristics are presented in Table 1. A total of 21,481 patients with non-renal SLE were included. All covariates were balanced in each comparison after propensity score overlap weighting. The mean age was 45 years and 94% of the patients were female.
Table 1. Baseline patient characteristics*
|
CKD, chronic kidney disease; ER, emergency room; IQR, interquartile range; SD, standard deviation; SLE, systemic lupus erythematosus. |
||||
|
Characteristic, % |
Belimumab (n = 3,955) |
Azathioprine (n = 6,957) |
Methotrexate (n = 8,917) |
Mycophenolate (n = 8,617) |
|---|---|---|---|---|
|
Mean age (SD), years |
44.2 (13.2) |
44.7 (15.5) |
47.5 (14.7) |
43.9 (16.1) |
|
Female |
95.0 |
92.0 |
93.0 |
88.6 |
|
Race/ethnicity |
||||
|
Asian |
2.1 |
2.3 |
1.6 |
3.0 |
|
Black |
25.1 |
32.8 |
26.3 |
37.1 |
|
Hispanic |
7.5 |
10.4 |
8.7 |
11.7 |
|
Other |
7.9 |
8.0 |
8.8 |
8.3 |
|
White |
57.4 |
46.5 |
54.6 |
39.8 |
|
CKD stage ≥3 |
12.8 |
15.6 |
11.5 |
23.5 |
|
Mean Charlson Comorbidity Index (SD) |
0.91 (0.85) |
0.98 (1.03) |
0.86 (0.98) |
1.14 (1.22) |
|
SLE Severity Index |
||||
|
Mild |
53.7 |
51.9 |
65.0 |
46.5 |
|
Moderate |
32.4 |
31.9 |
24.1 |
34.4 |
|
Severe |
13.9 |
16.2 |
10.9 |
19.1 |
|
Medication Use |
||||
|
Glucocorticoids |
61.5 |
54.9 |
50.7 |
54.0 |
|
Hydroxychloroquine |
54.2 |
45.1 |
45.9 |
40.5 |
|
Azathioprine |
14.8 |
— |
5.9 |
11.3 |
|
Belimumab |
— |
3.3 |
2.6 |
3.4 |
|
Methotrexate |
20.3 |
10.7 |
— |
8.3 |
|
Mycophenolate |
16.3 |
9.1 |
5.0 |
— |
|
Other oral immunosuppressant |
9.7 |
5.7 |
6.0 |
3.4 |
|
Rituximab |
2.4 |
1.7 |
1.2 |
1.9 |
|
Cyclophosphamide |
0.6 |
1.0 |
0.5 |
1.8 |
|
Healthcare Utilization |
||||
|
Median outpatient visits (IQR) |
3 (6) |
3 (7) |
2 (6) |
3 (7) |
|
ER/Inpatient visits |
19.4 |
25.7 |
20.9 |
30.9 |
|
Prior hospitalized infection |
1.3 |
3.0 |
2.2 |
4.3 |
We are pleased to present below a visual abstract summarizing the key results.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
